Liver Disease Clinical Trials

A listing of Liver Disease medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

Coronado California 92118

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Pasadena California 91105

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Rialto California 92377

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Colorado

Contact Research Site Directly
Englewood Colorado 80113

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

Contact Research Site Directly
Englewood Colorado 80113

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Englewood Colorado 80113

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Florida

Gastro Florida
Clearwater Florida 33762

TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

Gastro Florida
Clearwater Florida 33762

TARGET-PBC: A 5-year longitudinal observational study of patients with primary biliary cholangitis

Contact Research Site Directly
Wellington Florida 33414

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

Contact Research Site Directly
Wellington Florida 33414

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Miami Florida 33136

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Tampa Florida

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

Wellington Florida 33414

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Georgia

Contact Research Site Directly
Marietta Georgia 30060

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

Contact Research Site Directly
Marietta Georgia 30060

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Atlanta Georgia 30322

A clinical trial to evaluate treatments using Magnetic Resonance Imaging (MRI) for patients with Non-alcoholic Fatty Liver Disease

Marietta Georgia 30060

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Maryland

Baltimore Maryland 21202

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Catonsville Maryland 21228

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Massachusetts

Boston Massachusetts 02115

A clinical research study of Lovaza (omega-3-acid ethyl ester) and corn oil for the treatment of Liver Disease or Short Bowel Syndrome

Boston Massachusetts

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

Michigan

Novi Michigan 48377

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Mississippi

Jackson Mississippi 39216

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

New York

Research Site
Additional Locations New York

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Biomedical Research Alliance of New York
Manhasset New York 11030

Non-Alcoholic Steatohepatitis (NASH) cirrhosis

Contact Research Site Directly
New York New York 10016

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Manhasset New York 11030

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

New York New York

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

New York New York 10016

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Rochester New York 14642

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

North Carolina

Wake Research Associates
Raleigh North Carolina 27612

Fatty Liver (Nonalcoholic Steatohepatitis - NASH)

View More ▼

Fayetteville North Carolina 28304

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Statesville North Carolina 28677

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Ohio

Canton Ohio

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

Cleveland Ohio 44106

Patients are needed to participate in a clinical research study evaluating Solithromycin for the treatment of Nonalcoholic Steatohepatitis without Cirrhosis

Pennsylvania

Pittsburgh Pennsylvania 15213

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

South Carolina

PMG Research of Charleston
Charleston South Carolina 29464

Nonalcoholic Fatty Liver Disease (NAFLD)

Tennessee

Contact Research Site Directly
Chattanooga Tennessee 37421

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

Contact Research Site Directly
Chattanooga Tennessee 37421

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

ClinSearch, LLC
Chattanooga Tennessee 37421

NASH (Nonalcoholic Steatohepatitis)

ClinSearch, LLC
Chattanooga Tennessee 37421

Non-alcoholic Steatohepatitis (NASH) or Fatty Liver Disease

View More ▼

Chattanooga Tennessee 37421

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Nashville Tennessee 37211

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Texas

Contact Research Site Directly
Richardson Texas 75082

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

Contact Research Site Directly
Richardson Texas 75082

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

Clinical Trials of Texas, Inc.
San Antonio Texas 78229

Fatty Liver Disease Research Study Enrolling

View More ▼

Austin Texas 78756

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis